Grant Awards

 

 

January

 

December

 

 

 

August

2017

 

2016

 

 

 

2016

$2,000 awarded to Gregory Cote MD, PhD at Massachusetts General Hospital for his project, ART Inhibition in ALT Positive Leiomyosarcoma and Osteosarcoma.  Funded by the Lissy McMahon Memorial fund.


$40,000 awarded to Dr. Matt van de Rijn for his project titled:  ROR2 and a Potential Target in Leiomyosarcoma.

$90,000 awarded to Dr. Matt van de Rijn for his continued work on LMS circulating DNA titled:  Using Circulating Tumor DNA as a Measure of Tumor Load and Response to Therapy.


$125,000 awarded from LMSdr to the international collaborative of Drs. Fletcher, van de Rijn, Chibon, Bauer and Langenau. Their study is titled:  Maximizing Therapeutic Response in Leiomyosarcoma.  This study was co-funded collaboratively with the Liddy Shriver Foundation and National Leiomyosarcoma Foundation.  In this project they will sequence the genome of LMS tumors, investigate the P13K-AKT-mTor pathway, and test therapies with new cell lines, mice and zebra fish.  Power Point Presentation from CTOS 2016

group-photo


 

June

 

2015

 

$110,000 awarded to Dr. Matt van de Rijn for his continued circulating DNA research on leiomyosarcoma.


July 2014 LMSarcoma Direct Research Foundation awards $110,000 to Dr. Matt van de Rijn for his LMS circulating tumor DNA research.  The first goal of this research project is to find a  blood test that allows a doctor to tell the difference between a benign leiomyoma (fibroid) in the uterus from a malignant leiomyosarcoma. The second goal  would be to test individual leiomyosarcoma patients for any residual disease after treatments with a ctDNA blood test.  Dr. van de Rijn also continues his other studies of leiomyosarcoma at the same time.

Results:

September 2013 LMSarcoma Direct Research Foundation and the Liddy Shriver Sarcoma Initiative collaborate together to  fund a $150,000 grant for promising leiomyosarcoma research by Dr. Matt van de Rijn at Stanford University.Results:


April 2011 LMSarcoma Direct Research Foundation and the Liddy Shriver Sarcoma Initiative are pleased to announce the joint funding of a $50,000 research grant to Dr. Matt van de Rijn of Stanford University.Results:


January 2010 $25,000 was awarded to Dr. Sandra Orsulic of Cedars Sinai Medical Center in Los Angeles, CA. This is the second installment of a $50,000 grant provided by LMSarcoma Direct Research Foundation. Dr. Orsulic has also received grants from NIH (R01-CA103924), Ovarian Cancer Research Fund, the Liddy Shriver Sarcoma Initiative and the Sarcoma Foundation of America.Results:


November 2009 LMSarcoma Direct Research Foundation awards a $50,000 research grant to Dr. van de Rijn of Stanford University for his ongoing investigations of leiomyosarcoma.Results:


August 2009 $25,000 was awarded to Dr. Sandra Orsulic of Cedars Sinai Medical Center in Los Angeles, CA. This is the first installment of a $50,000 grant provided by LMSarcoma Direct Research Foundation. Dr. Orsulic has also received grants from NIH (R01-CA103924), Ovarian Cancer Research Fund, Liddy Shriver Sarcoma Initiative and the Sarcoma Foundation of America. 


April 2008 LMSarcoma Direct Research Foundation awards a $50,000 research grant to Drs. Matt van de Rijn of  Stanford University; Jonathan Fletcher of Dana Farber Cancer Center and Chris Coreless of Washington State University for  a collaborative research project on leiomyosarcoma.Results:


June 2007 LMSarcoma Direct Research Foundation grants $25,000 along with $25,000 from the Liddy Shriver Foundation ($50,000 total grant) to Dr. Eva Hernando of New York University School of Medicine for LMS research.Results:


February 2007  $1,000 donated to the ACOR Listserve for an equipment failure problem. ACOR is utilized by LMS patients and loved ones to share information and support.  Communication on ACOR made the ongoing LMS paraffin tumor block drive possible for research.


December 2006 $40,000 granted to  Dr. Matt van de Rijn at Stanford University to perform a microarray analysis of LMS from the paraffin tumor blocks donated by LMS patients worldwide to the LMS Tissue Bank at Stanford. Most of the above studies used these paraffin blocks.